

Curriculum Vitae

Name: Dr Alberto Fusi	
Present appointment: Medical Oncologist	
Address:	
Charitéplatz 1 10117 Berlin	
Telephone number: +49 30 450 564 622	Email address: Alberto.Fusi@charite.de
Qualifications (include DATE and INSTITUTION):	
Istituto Nazionale Tumori – Milan; University of Milan (05/2002 – 11/2005): Resident in Medical Oncology at Oncology Medical Dept. 2 (Director: Prof. Emilio Bajetta) of Istituto Nazionale Tumori of Milan, University of Milan.	
Specialist in Medical Oncology: 70/70 with honors; First academic session 2002; Medical Licensing Examination at Ordine dei Medici of Brescia; Italian national boards for the qualification to the profession of Physician.	
Medical School of the University of Brescia (10/1995 – 10/2001): Thesis in Molecular Oncology with Prof. Alberto Albertini, Awarded Medical doctor 110/110 with honors.	
Spedali Civili di Brescia - Dept of Medical Oncology (10/1998 – 10/2001): Internship in Medical Oncology – Internal fellow	
Spedali Civili di Brescia - Clinical Laboratory II (03/2000 – 10/2001): Internship in Translational Research – Internal fellow; Evaluation of VEGF and Her-2 levels in serum of patients affected by metastatic breast cancer	
Professional registration: (name of body, registration number and date of registration)	
General Medical Council reference number: 7240846; 20/07/2012	
Appointments:	
Charité – Campus Benjamin Franklin - Berlin (03/2008 – 07/2012): Hematology and Oncology Department; Medical oncologist, Lab Team leader for the evaluation and characterization of circulating tumour cells in patients with solid tumours. Clinical activity with patients affected by uveal and cutaneous melanoma and supervision of junior residents and scientists. CTC Scientist involved in the IMI-founded Oncotrack project,	
Charité – Campus Benjamin Franklin - Berlin (03/2006– 03/2008): Hematology and Oncology Department, Postdoctoral fellow involved in translational research studies and coordination of a side study of the EORTC 18991 trial.	
The Christie Hospital NHS Foundation Trust - Manchester (08/2012-09/2015): Medical Oncologist working within the Melanoma (Lead Dr. Lorigan) and Lung Cancer Team (Lead Dr. Blackhall). PI and Sub-I of several clinical trials. Translational research in cooperation with the group of Richard Marais and Caroline Dive	
Charité - Comprehensive Cancer Centre - Berlin (10/2015 - ongoing): Lead of the Melanoma Clinical Trials Unit	

Curriculum Vitae

List of publications (from 2011)

- Fusi A, Festino L, Botti G, Masucci G, Melero I, Lorigan P, Ascierto PA. PD-L1 expression as a potential predictive biomarker. *Lancet Oncol*. 2015; 16:1285-7.
- Howell M, Lee R, Bowyer S, Fusi A, Lorigan P. Optimal management of immune-related toxicities associated with checkpoint inhibitors in lung cancer. *Lung Cancer*. 2015; 88:117-23.
- Girotti MR, Lopes F, Preece N, Niculescu-Duvaz D, Zambon A, Davies L, Whittaker S, Saturno G, Viros A, Pedersen M, Suijkerbuijk BM, Menard D, McLeary R, Johnson L, Fish L, Ejima S, Sanchez-Laorden B, Hohloch J, Carragher N, Macleod K, Ashton G, Marusiak AA, Fusi A, Brognard J, Frame M, Lorigan P, Marais R, Springer C. Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma. *Cancer Cell*. 2015; 27:85-96.
- Fusi A, Hodgetts J, Dennis M, Lorigan P. Vemurafenib-induced nonautoimmune haemolytic anaemia. *Melanoma Res*. 2014; 24:418-9.
- Khoja L, Lorigan P, Dive C, Keilholz U, Fusi A. Circulating tumor cells as tumor biomarkers in melanoma: detection methods and clinical relevance. *Ann Oncol* 2014; 26:33-9
- Pfisterer K, Fusi A, Klinghammer K, Knödler M, Nonnenmacher A, Keilholz U. PI3K/PTEN/AKT/mTOR pathway genetic variations are associated with the clinical outcome in patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment. *Head Neck* 2014; 37:471-8.
- Polanski R, Hodgkinson CL, Fusi A, Nonaka D, Priest L, Kelly P, Trapani F, Bishop PW, White A, Critchlow SE, Smith PD, Blackhall F, Dive C, Morrow C. Inhibition of lactate transport as therapeutic target in SCLC. *Clin Cancer Res*. 2014 20:926-37
- Gross A, Niemetz-Rahn A, Nonnenmacher A, Tucholski J, Fusi A, Keilholz U. Expression and activity of EGFR in human cutaneous melanoma cell lines and influence of vemurafenib on the EGFR-pathway. *Target Oncol* 2014; 10:77-84.
- Fusi A, Metcalf R, Krebs M, Dive C, Blackhall F. Clinical utility of circulating tumor cell detection in non-small- cell lung cancer. *Curr Treat Options Oncol*. 2013; 14:610-22.
- Busse A, Rapon J, Fusi A, Suci S, Nonnenmacher A, Santinami M, Kruit WH, Testori A, Punt CJ, Dalglish AG, Spatz A, Eggermont AM, Keilholz U. Analysis of surrogate gene expression markers in peripheral blood of melanoma patients to predict treatment outcome of adjuvant pegylated interferon alpha 2b (EORTC 18991 side study). *Cancer Immunol Immunother*. 2013, 62:1223-33
- Busse A, Letsch A, Fusi A, Nonnenmacher A, Stather D, Ochsenreither S, Regenbrecht CR, Keilholz U. Characterization of small spheres derived from various solid tumor cell lines: are they suitable targets for T cells? *Clin Exp Metastasis*. 2013, 30:781-91
- Puggina A, Kümmerlen V, Keilholz U, Fusi A. Biclinal non-small cell lung cancer in disseminated tumor cells and tissue. *J Thor Oncol* 2012, 7:1202-3.
- Fusi A, Z Liu, Kümmerlen V, Nonnenmacher A, Jeske J, Keilholz U. Expression of chemokine receptors on circulating tumor cells in patients with solid tumor. *J Transl Med*. 2012, 10:52.
- Ochsenreither S, Fusi A, Geikowski A, Stather D, Busse A, Stroux A, Letsch A, Keilholz U. Wilms' tumor protein 1 (WT1) peptide vaccination in AML patients: predominant TCR CDR3 β sequence associated with remission in one patient is detectable in other vaccinated patients. *Cancer Immunol Immunother*. 2012, 61:313-22
- Hotz B, Keilholz U, Fusi A, Buhr HJ, Hotz HG. In vitro and in vivo antitumor activity of cetuximab in human gastric cancer cell lines in relation to epidermal growth factor receptor (EGFR) expression and mutational phenotype. *Gastric Cancer* 2012, in press.
- Liu Z, Fusi A, Schmittl A, Tinhofer I, Nonnenmacher A, Keilholz U. Negative enrichment by immunomagnetic nanobeads for unbiased characterization of circulating tumor cells from peripheral blood of cancer patients. *J Transl Med*. 2011; 9:70.
- Fusi A, Berdel R, Havemann S, Nonnenmacher A, Keilholz U. Enhanced detection of BRAF-mutants by pre-PCR cleavage of wild-type sequences revealed circulating melanoma cells heterogeneity. *Eur J Cancer* 2011; 47:1971-6.
- Hristozova T, Korschak R, Stromberger C, Fusi A, Liu Z, Weichert W, Stenzinger A, Budach V, Keilholz U, Tinhofer I. The presence of circulating tumor cells (CTCs) correlates with lymph node metastasis in nonresectable squamous cell carcinoma of the head and neck region (SCCHN). *Ann Oncol* 2011; 22:1878-85.

Curriculum Vitae

- Busse A, Asemissen AM, Nonnenmacher A, Braun F, Ochsenreither S, Stather D, Fusi A, Schmittel A, Miller K, Thiel E, Keilholz U. Immunomodulatory effects of sorafenib on peripheral immune effector cells in metastatic renal cell carcinoma. *Eur J Cancer* 2011; 47:690-6.
- Busse A, Asemissen AM, Nonnenmacher A, Ochsenreither S, Fusi A, Braun F, Stather D, Schmittel A, Miller K, Thiel E, Keilholz U. Systemic immune tuning in renal cell carcinoma: favorable prognostic impact of TGF-beta 1 mRNA expression in peripheral blood mononuclear cells. *J Immunother* 2011, 34:113-9.
- Ochsenreither S, Fusi A, Busse A, Bauer S, Scheibenbogen C, Stather D, Thiel E, Keilholz U, Letsch A. "Wilms Tumor Protein 1" (WT1) peptide vaccination-induced complete remission in a patient with acute myeloid leukemia is accompanied by the emerge of a predominant T-cell clone both in blood and bone marrow. *J Immunother* 2011, 34:85-91.
- Fusi A, Reichelt U, Busse A, Ochsenreither S, Rietz A, Maisel M, Keilholz U. Expression of the Stem Cell Markers Nestin and CD133 on Circulating Melanoma Cells. *J Invest Dermatol.* 2011, 131:487-94